8-KOther EventsExhibits & Filings

AGILENT TECHNOLOGIES, INC. 8-K Report, Corporate Update (Sep 3, 2024)

Filed September 3, 2024For Securities:A

Summary

Agilent Technologies, Inc. filed a Current Report on Form 8-K to incorporate by reference information from its previous filings, specifically to reflect a change in its operating segment reporting structure. The company has recasted its historical financial segment information to align with a reorganization announced in the first quarter of fiscal year 2024. This reorganization moved the cell analysis business from the 'Life Sciences and Applied Markets' segment to the 'Diagnostics and Genomics' segment. This 8-K filing serves to update the presentation of segment data within previously filed documents, primarily the Annual Report on Form 10-K for the year ended October 31, 2023. Investors should note that this report does not contain new financial information or updates on subsequent events beyond the segment recasting. For the most current financial performance and events, investors should refer to Agilent's most recent Form 10-Q filing for the quarter ended July 31, 2024.

Key Highlights

  • 1Agilent Technologies is filing an 8-K to reflect updated segment reporting.
  • 2The company has moved its cell analysis business from 'Life Sciences and Applied Markets' to 'Diagnostics and Genomics'.
  • 3This change was announced in Q1 FY2024 and aims to strengthen growth opportunities for both segments.
  • 4Historical financial segment information has been recast to conform to the new structure.
  • 5This filing recasts specific items in the Form 10-K for the year ended October 31, 2023.
  • 6The report does NOT include any new financial information or updates on events subsequent to the Form 10-K filing, other than segment adjustments.
  • 7Investors should consult the latest Form 10-Q for current financial performance and updates.

Frequently Asked Questions

The primary purpose of this 8-K filing is to incorporate by reference and present recasted historical segment financial information that reflects a previously announced change in Agilent's operating segments. Specifically, the cell analysis business was moved from the Life Sciences and Applied Markets segment to the Diagnostics and Genomics segment.

No, this filing does not contain any new financial results or updates on events occurring after the filing of the Annual Report on Form 10-K for the year ended October 31, 2023. It solely addresses the restatement of historical segment reporting due to a business structure change.

For the most current financial performance, events, and updates, investors should refer to Agilent's Quarterly Report on Form 10-Q for the quarterly period ended July 31, 2024, and other subsequent filings with the Securities and Exchange Commission.

Recasting historical segment information ensures that financial comparisons over time are consistent and accurately reflect the company's current reporting structure. This allows investors to better analyze trends and performance within each segment as they are now defined.